Heidi N. Leblanc

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity

Sean C. Bendall, Michael N. Alonso, J. Melrose, 2020, Nature Cancer.

In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

A. Korman, R. T. Bunch, M. Selby, 2014, Cancer Immunology Research.

Death Receptor Recruitment of Endogenous Caspase-10 and Apoptosis Initiation in the Absence of Caspase-8*

J. Blenis, A. Gazdar, A. Virmani, 2001, The Journal of Biological Chemistry.

Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax

Peter Schow, D. Lawrence, A. Ashkenazi, 2002, Nature Medicine.

Apo2L/TRAIL and its death and decoy receptors

A. Ashkenazi, H. LeBlanc, Heidi N. Leblanc, 2003, Cell Death and Differentiation.

A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer

J. Sage, Kwon-Sik Park, D. Menezes, 2018, Clinical Cancer Research.

In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

A. Korman, M. Selby, Susan Wong, 2014, Cancer Immunology Research.

TWEAK Attenuates the Transition from Innate to Adaptive Immunity

D. Lawrence, D. Danilenko, H. Maecker, 2005, Cell.